Enhanced recovery from ischemia-reperfusion injury in PI3Kα dominant negative hearts: Investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling

Journal of Molecular and Cellular Cardiology

Volumn 54, Issue 1, 2013, Pages 9-18

  McLean, Brent A ^a   Kienesberger, Petra C ^a   Wang, Wang ^a   Masson, Grant ^a   Zhabyeyev, Pavel ^a   Dyck, Jason R B ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Akt; Glucose oxidation; Ischemia reperfusion; MAPK; PI3K; Working heart

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; GLUCOSE OXIDATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART PERFUSION; HEART PROTECTION; INTRACELLULAR SIGNALING; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; UPREGULATION; WILD TYPE;

ANIMALS; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIC AMP; FEMALE; GENES, DOMINANT; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; HEART RATE; ISOENZYMES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATION-REDUCTION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SECOND MESSENGER SYSTEMS; VENTRICULAR PRESSURE;

MURINAE; MUS;

EID: 84869228814     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.10.015     Document Type: Article

References (54)

1. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
2. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988.
3. Hausenloy D.J., Tsang A., Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005, 15:69-75.
4. Tong H., Imahashi K., Steenbergen C., Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 2002, 90:377-379.
5. Crackower M.A., Oudit G.Y., Kozieradzki I., Sarao R., Sun H., Sasaki T., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110:737-749.
6. Ban K., Cooper A.J., Samuel S., Bhatti A., Patel M., Izumo S., et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 2008, 103:643-653.
7. Haubner B.J., Neely G.G., Voelkl J.G., Damilano F., Kuba K., Imai Y., et al. PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS One 2010, 5:e9350.
8. Yamashita K., Kajstura J., Discher D.J., Wasserlauf B.J., Bishopric N.H., Anversa P., et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 2001, 88:609-614.
9. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004, 61:448-460.
10. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:12355-12360.
11. Lin R.C., Weeks K.L., Gao X.M., Williams R.B., Bernardo B.C., Kiriazis H., et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 2010, 30:724-732.
12. Oudit G.Y., Penninger J.M. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009, 82:250-260.
13. McMullen J.R., Amirahmadi F., Woodcock E.A., Schinke-Braun M., Bouwman R.D., Hewitt K.A., et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 2007, 104:612-617.
14. Cross M.J., Stewart A., Hodgkin M.N., Kerr D.J., Wakelam M.J. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 1995, 270:25352-25355.
15. Nakanishi S., Kakita S., Takahashi I., Kawahara K., Tsukuda E., Sano T., et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 1992, 267:2157-2163.
16. Liu Y., Shreder K.R., Gai W., Corral S., Ferris D.K., Rosenblum J.S. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol 2005, 12:99-107.
17. Ferby I.M., Waga I., Sakanaka C., Kume K., Shimizu T. Wortmannin inhibits mitogen-activated protein kinase activation induced by platelet-activating factor in guinea pig neutrophils. J Biol Chem 1994, 269:30485-30488.
18. Guo D., Kassiri Z., Basu R., Chow F.L., Kandalam V., Damilano F., et al. Loss of PI3K{gamma} enhances cAMP-dependent MMP remodeling of the myocardial N-Cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res 2010, 107:1275-1289.
19. Oudit G.Y., Kassiri Z., Zhou J., Liu Q.C., Liu P.P., Backx P.H., et al. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res 2008, 78:505-514.
20. Zhong J., Basu R., Guo D., Chow F.L., Byrns S., Schuster M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010, 122:717-728.
21. Kuang M., Febbraio M., Wagg C., Lopaschuk G.D., Dyck J.R. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 2004, 109:1550-1557.
22. Dyck J.R., Hopkins T.A., Bonnet S., Michelakis E.D., Young M.E., Watanabe M., et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006, 114:1721-1728.
23. Oudit G.Y., Sun H., Kerfant B.G., Crackower M.A., Penninger J.M., Backx P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004, 37:449-471.
24. Juhaszova M., Zorov D.B., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009, 104:1240-1252.
25. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000, 19:2537-2548.
26. Guo D., Kassiri Z., Basu R., Chow F.L., Kandalam V., Damilano F., et al. Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res 2010, 107:1275-1289.
27. Wu C.Y., Jia Z., Wang W., Ballou L.M., Jiang Y.P., Chen B., et al. PI3Ks maintain the structural integrity of T-tubules in cardiac myocytes. PLoS One 2011, 6:e24404.
28. Kunuthur S.P., Mocanu M.M., Hemmings B.A., Hausenloy D.J., Yellon D.M. The Akt1 isoform is an essential mediator of ischaemic preconditioning. J Cell Mol Med 2012, 16:1739-1749.
29. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008, 105:8292-8297.
30. Katada T., Kurosu H., Okada T., Suzuki T., Tsujimoto N., Takasuga S., et al. Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors. Chem Phys Lipids 1999, 98:79-86.
31. Fruman D.A., Mauvais-Jarvis F., Pollard D.A., Yballe C.M., Brazil D., Bronson R.T., et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet 2000, 26:379-382.
32. Liu Q., Docherty J.C., Rendell J.C., Clanachan A.S., Lopaschuk G.D. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002, 39:718-725.
33. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258.
34. Ussher J.R., Wang W., Gandhi M., Keung W., Samokhvalov V., Oka T., et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 2012, 94:359-369.
35. Matsui T., Nagoshi T., Hong E.G., Luptak I., Hartil K., Li L., et al. Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab 2006, 290:E789-E797.
36. O'Neill B.T., Kim J., Wende A.R., Theobald H.A., Tuinei J., Buchanan J., et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 2007, 6:294-306.
37. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
38. Dyck J.R., Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J Physiol 2006, 574:95-112.
39. Beauloye C., Bertrand L., Horman S., Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011, 90:224-233.
40. Kudo N., Barr A.J., Barr R.L., Desai S., Lopaschuk G.D. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995, 270:17513-17520.
41. Dyck J.R., Kudo N., Barr A.J., Davies S.P., Hardie D.G., Lopaschuk G.D. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase. Eur J Biochem 1999, 262:184-190.
42. Treebak J.T., Glund S., Deshmukh A., Klein D.K., Long Y.C., Jensen T.E., et al. AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes 2006, 55:2051-2058.
43. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
44. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010, 2:16ra7.
45. Lips D.J., Bueno O.F., Wilkins B.J., Purcell N.H., Kaiser R.A., Lorenz J.N., et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 2004, 109:1938-1941.
46. Bueno O.F., Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002, 91:776-781.
47. Vassalli G., Milano G., Moccetti T. Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation. J Transplant 2012, 2012:928954.
48. Chai W., Wu Y., Li G., Cao W., Yang Z., Liu Z. Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2008, 294:E183-E189.
49. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
50. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
51. Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19:575-586.
52. Garrett J.T., Chakrabarty A., Arteaga C.L. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. Oncotarget 2011, 2:1314-1321.
53. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
54. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.